View Financial HealthProteome Sciences 配当と自社株買い配当金 基準チェック /06Proteome Sciences配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdomお知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation Sお知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct Listingお知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdomお知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United Kingdomお知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.決済の安定と成長配当データの取得安定した配当: PMSN.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PMSN.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Proteome Sciences 配当利回り対市場PMSN.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PMSN.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Life Sciences)0.7%アナリスト予想 (PMSN.F) (最長3年)n/a注目すべき配当: PMSN.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PMSN.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PMSN.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PMSN.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 00:50終値2026/03/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Proteome Sciences plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMichael Thomas CooperEdison Investment Research
お知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.
お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdom
お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation S
お知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom
お知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025
お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United Kingdom
お知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.